Navigation Links
BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
Date:8/19/2007

WOBURN, Mass., Aug. 15 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Dr. Thaddeus Pullano, 53, as Vice President of Quality Assurance.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070815/NYW022 )

Previously, Dr. Pullano served as the Vice President of Quality Systems for Acambis from 2003 to 2007. In this role, he was responsible for all aspects of Quality Systems, including oversight of vaccine manufacturing and clinical quality assurance. Prior to joining Acambis, Dr. Pullano was responsible for quality assurance at Transkaryotic Therapies as the Company transitioned from R&D to manufacturing operations. He has also held a number of positions in quality assurance at Wyeth Vaccines. Dr. Pullano holds a Ph.D. in Biochemistry from the University of Southern California and a BS in Biochemistry from the State University of New York at Binghamton.

Philip Astley-Sparke, President & CEO of BioVex Inc, said:

"Thad has direct and extensive experience with quality systems supporting the manufacture and release of biologics for clinical trials and commercial sale. He becomes part of the core team dedicated to moving our Woburn manufacturing facility, which will supply Phase III and launch grade material, towards operational status."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX(GM-CSF), is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX(GM-CSF) is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX(GM-CSF) has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX(GM-CSF) as stand alone therapy in patients with stage IIIc and stage IV metastatic disease.

The Company's second program is a vaccine for genital herpes, ImmunoVEX(HSV2), which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX(HSV2) is scheduled to initiate later this year.

For more information visit the company's website at http://www.biovex.com.


'/>"/>
SOURCE BioVex

Copyright©2007 PR Newswire.

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):